Markov模型在上市后中药经济学评价中的应用  

Application of Markov model in post-marketing pharmacoeconomic evaluation of traditional Chinese medicine

作　　者：王昕[1,2] 苏霞[1] 孙文韬[1] 谢雁鸣[3] 王永炎[3] 

机构地区：[1]北京博诺威医药科技发展有限公司,北京100024 [2]中国中医科学院博士后流动站,北京100700 [3]中国中医科学院中医临床基础医学研究所,北京100700

出　　处：《中国中药杂志》2011年第20期2844-2847,共4页China Journal of Chinese Materia Medica

基　　金：国家"重大新药创制"科技重大专项(2009ZX09502-030);中国中医科学院自主选题研究项目(Z0133)

摘　　要：在中药上市后研究中,药物经济学评价具有重要的应用意义。然而已有中药经济学文献大多无法全面准确体现出中药所独有的整体治疗效果。针对中药本身具有的特殊性,笔者推荐在上市后中药经济学评价中采用Markov方法学模型,并从研究时限的外推、效用指标的契合以及综合结果的衡量3方面对模型应用的可行性进行探讨。此外,Markov模型的方法学探索,能够促进一批具有中医特色的、可应用于中医药疗效评价的生命质量量表的制定,推动上市后中药经济学评价方法学进一步向前发展。In post-marketing study of traditional Chinese medicine（ TCM）, pharmacoeconomic evaluation has an important applied significance. However, the economic literatures of TCM have been unable to fully and accurately reflect the unique overall outcomes of treatment with TCM. For the special nature of TCM itself, we recommend that Markov model could be introduced into postmarketing pharmacoeconomic evaluation of TCM, and also explore the feasibility of model application. Markov model can extrapolate the study time horizon, suit with effectiveness indicators of TCM, and provide measurable comprehensive outcome. In addition, Markov model can promote the development of TCM quality of life scale and the methodology of post-marketing pharmacoeconomic evaluation.

关 键 词：上市后研究 中药经济学评价 MARKOV模型 

分 类 号：R288[医药卫生—中药学]